2:02 PM
 | 
Dec 06, 2018
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Inc. (Bedford, Mass.) presented the preclinical data for its Dravet syndrome antisense oligonucleotide (ASO) therapy that CEO Ed Kaye said helped it raise its $90 million series B round in October.

In a mouse model of Dravet syndrome, 99% of mice treated with an intracerebroventricular injection of an ASO targeting mutant sodium voltage-gated channel α subunit 1 (Nav1.1; SCN1A) survived, whereas 50% of mice treated with vehicle died.

The ASO also increased Nav1.1 mRNA expression and levels of its corresponding protein to...

Read the full 400 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >